Valproic Acid Trial Failure in Progressive Supranuclear Palsy

Valproic Acid Trial Failure in Progressive Supranuclear Palsy

Overview

Valproic Acid Trial Failure in Progressive Supranuclear Palsy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Valproic Acid Trial Failure in Progressive Supranuclear Palsy</th>
</tr>
<tr>
<td class="label">Rationale</td>
<td>Evidence</td>
</tr>
<tr>
<td class="label">Tau acetylation</td>
<td>HDAC6 regulates tau acetylation/phosphorylation</td>
</tr>
<tr>
<td class="label">Neuroprotection</td>
<td>VPA protects against various insults</td>
</tr>
<tr>
<td class="label">Anti-inflammatory</td>
<td>Reduces glial activation</td>
</tr>
<tr>
<td class="label">Preclinical data</td>
<td>Mixed results in tau models</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Completed</td>
</tr>
<tr>
<td class="label">Design</td>
<td>Randomized, double-blind, placebo-controlled</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>12 months</td>
</tr>
<tr>
<td class="label">Primary endpoint</td>
<td>Change in PSP Rating Scale (PSPRS)</td>
</tr>
<tr>
<td class="label">Outcome</td>
<td>Valproic Acid</td>
</tr>
<tr>
<td class="label">Motor function</td>
<td>Worsened</td>
</tr>
<tr>
<td class="label">Cognitive function</td>
<td>Stable</td>
</tr>
<tr>
<td class="label">Brain atrophy</td>
<td>Similar rates</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Sedation</td>
<td>Common</td>
</tr>
<tr>
<td class="label">Weight gain</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Liver enzymes</td>
<td>Elevated</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Limitation</td>
</tr>
<tr>
<td class="label">Sample size</td>
<td>May have been underpowered</td>
</tr>
<tr>
<td class="label">Endpoint</td>
<td>PSPRS may lack sensitivity</td>
</tr>
<tr>
<td class="label">Biomarkers</td>
<td>No target engagement biomarkers</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">HDAC6</td>
<td>Selective inhibitors</td>
</tr>
<tr>
<td class="label">Acetyltransferases</td>
<td>p300/CBP inhibitors</td>
</tr>
<tr>
<td class="label">Acetylation readers</td>
<td>Bromodomain inhibitors</td>
</tr>
<tr>
<td class="label">Recommendation</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Longer trials</td>
<td>Disease modification needs time</td>
</tr>
<tr>
<td class="label">Multiple endpoints</td>
<td>Capture diverse outcomes</td>
</tr>
<tr>
<td class="label">Biomarker substudies</td>
<td>Understand mechanisms</td>
</tr>
<tr>
<td class="label">Adaptive designs</td>
<td>Increase efficiency</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>Anti-tau antibody</td>
</tr>
<tr>
<td class="label">Zagotenemab</td>
<td>Anti-tau antibody</td>
</tr>
<tr>
<td class="label">LMTX</td>
<td>Tau aggregation inhibitor</td>
</tr>
<tr>
<td class="label">CBD</td>
<td>Unclear</td>
</tr>
</table>

The valproic acid trial (NCT00385710) in Progressive Supranuclear Palsy (PSP) represents a notable failure in the development of disease-modifying treatments for tauopathies. This page documents the trial, analyzes why [HDAC](/entities/hdac-enzymes) inhibition with valproic acid failed to provide benefit, and extracts lessons learned for future clinical trials in PSP and related disorders [1].

Trial Background

Rationale for Valproic Acid in PSP

Valproic acid (VPA) is a mood stabilizer and anticonvulsant with histone deacetylase (HDAC) inhibitor activity. The preclinical rationale for testing in PSP included:

Trial Design (NCT00385710)

Trial Results

Primary Outcome

• Result: No significant difference between valproic acid and placebo
• PSPRS change: Similar progression in both arms
• Conclusion: Trial failed to meet primary endpoint

Secondary Outcomes

Safety Profile

Failure Analysis

Why the Trial Failed

1. Wrong Target or Pathway

HDAC inhibition may not be the right approach for PSP:

• Tau pathology complexity: Acetylation is one of many post-translational modifications
• HDAC isoform specificity: VPA inhibits multiple HDACs, not specifically HDAC6
• Tau clearance mechanisms: May need different approach than acetylation modulation [2]

2. Insufficient Target Engagement

• CNS penetration: Valproic acid brain levels may have been inadequate
• HDAC inhibition: May not have achieved sufficient HDAC inhibition in brain
• Duration: 12 months may be insufficient to see disease modification

3. Patient Population Issues

• Diagnostic accuracy: Clinical diagnosis of PSP has limited specificity
• Disease stage: Patients may have been too advanced
• Heterogeneity: PSP includes multiple clinical variants

4. Trial Design Limitations

Mechanistic Insights

What We Learned About HDAC6

HDAC6 remains a valid target, but with caveats:

• Subcellular localization: Cytoplasmic HDAC6 is relevant
• Specificity matters: Selective HDAC6 inhibitors may work better
• Combination approaches: May need more than HDAC inhibition alone

Alternative Approaches

Since valproic acid failed, other strategies are being pursued:

Lessons Learned for Future Trials

1. Target Validation

• Better preclinical models: Need models with human tau
• Biomarker development: Confirm target engagement before large trials
• Mechanistic studies: Understand which HDAC isoforms matter

2. Patient Selection

• Biomarker-enriched trials: Use tau PET or CSF markers
• Early intervention: Treat patients earlier in disease course
• Genetic stratification: Consider [MAPT](/proteins/tau) mutations

3. Trial Design

4. Regulatory Considerations

• Accelerated approval pathways: Consider biomarkers
• Natural history studies: Improve understanding of progression
• Patient registries: Build infrastructure

Current Landscape of PSP Treatments

In Development

Lessons from Valproic Acid

The failure of valproic acid highlights:

Key Publications

See Also

• [Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy)
• [PSP Treatment](/therapeutics/progressive-supranuclear-psp-psp-treatment)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Tau-Targeted Therapeutics](/therapeutics/tau-targeted-therapeutics)
• [HDAC Inhibitors in Neurodegeneration](/therapeutics/hdac-inhibitors-neurodegeneration)
• [Neuroinflammation in PSP](/mechanisms/neuroinflammation-psp)

External Links

• [CurePSP Foundation](https://www.psp.org)
• [ClinicalTrials.gov - NCT00385710](https://clinicaltrials.gov)
• [Tau Consortium](https://www.tauconsortium.org)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK1/Parkin Mitophagy Dysfunction](/hypothesis/h-seaad-v4-5a7a4079) — <span style="color:#81c784;font-weight:600">0.62</span> · Target: SIRT3
• [Astrocyte-Mediated Neuronal Epigenetic Rescue](/hypothesis/h-8fe389e8) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: HDAC
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1

Related Analyses:

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) &#x1f504;
• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;
• [Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v4-20260402065846) &#x1f504;